Skip to main content
NEO:HALO

Halozyme Therapeutics Competitors

C$43.41
+1.64 (+3.93 %)
(As of 05/14/2021 01:21 PM ET)
Add
Compare
Today's Range
C$41.69
C$43.43
50-Day Range N/A
52-Week Range
C$22.11
C$56.40
Volume9,947 shs
Average Volume1.32 million shs
Market CapitalizationC$6.18 billion
P/E Ratio47.70
Dividend YieldN/A
BetaN/A

Competitors

Halozyme Therapeutics (NEO:HALO) Vs. CHV, PREV, COM, MYM, CURE, and LTY

Should you be buying HALO stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Halozyme Therapeutics, including (CHV) (CHV), (PREV) (PREV), 138267 (COM.TO) (COM), 17031 (MYM), Direxion Daily Healthcare Bull 3X Shares (CURE), and Liberty Biopharma (LTY).

Halozyme Therapeutics (NEO:HALO) and (CHV) (CNSX:CHV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and (CHV), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
(CHV)0000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and (CHV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
(CHV)N/AN/AN/A

Valuation & Earnings

This table compares Halozyme Therapeutics and (CHV)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million23.10$129.57 millionC$0.9147.70
(CHV)N/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than (CHV).

Summary

Halozyme Therapeutics beats (CHV) on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics (NEO:HALO) and (PREV) (CNSX:PREV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and (PREV), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
(PREV)0000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and (PREV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
(PREV)N/AN/AN/A

Valuation & Earnings

This table compares Halozyme Therapeutics and (PREV)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million23.10$129.57 millionC$0.9147.70
(PREV)N/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than (PREV).

Summary

Halozyme Therapeutics beats (PREV) on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics (NEO:HALO) and 138267 (COM.TO) (TSE:COM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and 138267 (COM.TO), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
138267 (COM.TO)0000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and 138267 (COM.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
138267 (COM.TO)N/AN/AN/A

Valuation & Earnings

This table compares Halozyme Therapeutics and 138267 (COM.TO)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million23.10C$129.57 millionC$0.9147.70
138267 (COM.TO)N/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than 138267 (COM.TO).

Summary

Halozyme Therapeutics beats 138267 (COM.TO) on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics (NEO:HALO) and 17031 (CNSX:MYM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and 17031, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
170310000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and 17031's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
17031N/AN/AN/A

Valuation & Earnings

This table compares Halozyme Therapeutics and 17031's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million23.10C$129.57 millionC$0.9147.70
17031N/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than 17031.

Summary

Halozyme Therapeutics beats 17031 on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics (NEO:HALO) and Direxion Daily Healthcare Bull 3X Shares (CNSX:CURE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Halozyme Therapeutics and Direxion Daily Healthcare Bull 3X Shares' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme TherapeuticsN/AN/AN/A
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and Direxion Daily Healthcare Bull 3X Shares, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics00014.00
Direxion Daily Healthcare Bull 3X Shares0000N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Valuation & Earnings

This table compares Halozyme Therapeutics and Direxion Daily Healthcare Bull 3X Shares' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme TherapeuticsC$267.59 million23.10$129.57 millionC$0.9147.70
Direxion Daily Healthcare Bull 3X SharesN/AN/AN/AN/AN/A

Halozyme Therapeutics has higher revenue and earnings than Direxion Daily Healthcare Bull 3X Shares.

Summary

Halozyme Therapeutics beats Direxion Daily Healthcare Bull 3X Shares on 2 of the 2 factors compared between the two stocks.

Liberty Biopharma (CVE:LTY) and Halozyme Therapeutics (NEO:HALO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Profitability

This table compares Liberty Biopharma and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Liberty BiopharmaN/AN/AN/A
Halozyme TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Liberty Biopharma and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Liberty Biopharma0000N/A
Halozyme Therapeutics00014.00

Halozyme Therapeutics has a consensus target price of C$0.24, indicating a potential downside of 99.45%. Given Halozyme Therapeutics' higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than Liberty Biopharma.

Earnings & Valuation

This table compares Liberty Biopharma and Halozyme Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liberty BiopharmaN/AN/AN/AC($0.16)-12.66
Halozyme TherapeuticsC$267.59 million23.10C$129.57 millionC$0.9147.70

Halozyme Therapeutics has higher revenue and earnings than Liberty Biopharma. Liberty Biopharma is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats Liberty Biopharma on 5 of the 5 factors compared between the two stocks.


Halozyme Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Up
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00Gap Up
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.